Showing results (101-110 of 157) with videos related to
Sort By:
Pageof 16
The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.Journal of the National Cancer Institute|April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCMakoto Nishio, Enriqueta Felip, Sergey Orlov, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 15, 2022
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in AsiaTetsuya Mitsudomi, Daniel Tan, James Chih-Hsin Yang, et al.JTO Clinical and Research Reports|August 14, 2025
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLCJay M Lee, Jean-Louis Pujol, Jun Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX StudyD Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.Nature Communications|February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi-Long Wu, et al.The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.Pageof 16